| Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer J Koh, JY Hur, KY Lee, MS Kim, JY Heo, BM Ku, JM Sun, SH Lee, JS Ahn, ... Scientific reports 10 (1), 18994, 2020 | 71 | 2020 |
| Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients SM Bray, J Lee, ST Kim, JY Hur, PJ Ebert, JN Calley, IH Wulur, ... Scientific reports 9 (1), 15365, 2019 | 68 | 2019 |
| MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC J Koh, Y Kim, KY Lee, JY Hur, MS Kim, B Kim, HJ Cho, YC Lee, YH Bae, ... European journal of immunology 50 (11), 1810-1819, 2020 | 61 | 2020 |
| The prognostic nutritional index predicts survival and identifies aggressiveness of gastric cancer WK Eo, HJ Chang, J Suh, J Ahn, J Shin, JY Hur, GY Kim, S Lee, S Park, ... Nutrition and cancer 67 (8), 1262-1269, 2015 | 46 | 2015 |
| Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment KH Kim, JY Hur, J Cho, BM Ku, J Koh, JY Koh, JM Sun, SH Lee, JS Ahn, ... Oncoimmunology 9 (1), 1722023, 2020 | 41 | 2020 |
| High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers JY Hur, J Chao, K Kim, ST Kim, KM Kim, SJ Klempner, J Lee Pathology-Research and Practice 216 (4), 152878, 2020 | 26 | 2020 |
| Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma H Kim, H Jeong, M Yamaguchi, I Sohn, SE Yoon, S Byeon, JY Hur, Y Koh, ... Blood, The Journal of the American Society of Hematology 136 (22), 2548-2556, 2020 | 22 | 2020 |
| Preoperative plateletcrit is a prognostic biomarker for survival in patients with non-small cell lung cancer JY Hur, HY Lee, HJ Chang, CW Choi, DH Kim, WK Eo Journal of Cancer 11 (10), 2800, 2020 | 17 | 2020 |
| Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas JY Hur, YJ Kim, SE Yoon, DS Son, WY Park, SJ Kim, D Park, WS Kim Annals of Hematology 99, 1293-1302, 2020 | 16 | 2020 |
| Characteristics and clinical outcomes of non-small cell lung cancer patients in Korea with MET exon 14 skipping JY Hur, BM Ku, JH Shim, HA Jung, JM Sun, SH Lee, JS Ahn, K Park, ... in vivo 34 (3), 1399-1406, 2020 | 14 | 2020 |
| Immunological characteristics of hyperprogressive disease in patients with non-small cell lung cancer treated with anti-PD-1/PD-L1 Abs KH Kim, JY Hur, J Koh, J Cho, BM Ku, JY Koh, JM Sun, SH Lee, JS Ahn, ... Immune Network 20 (6), 2020 | 13 | 2020 |
| High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer Y Kim, S Byeon, J Hur, K Lee, D Kim, JH Ahn, SH Lee, WK You, ST Kim, ... Journal of Cancer 10 (14), 3172, 2019 | 12 | 2019 |
| Clinical significance of C-reactive protein to lymphocyte count ratio as a prognostic factor for survival in non-small cell lung cancer patients undergoing curative surgical … JJ Hwang, JY Hur, W Eo, S An, DH Kim, S Lee Journal of Cancer 12 (15), 4497, 2021 | 10 | 2021 |
| Prognostic value of FOXP3+ regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma JY Hur, BM Ku, S Park, HA Jung, SH Lee, MJ Ahn Plos one 17 (10), e0274830, 2022 | 7 | 2022 |
| Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure JH Park, I Park, IH Kim, JY Hur, I Hwang, C Kim, HJ Kim, CH Maeng, ... Current Problems in Cancer 46 (3), 100848, 2022 | 6 | 2022 |
| Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study S Byeon, H Kim, J Kim, M Kwon, JY Hur, HG Jeon, SS Jeon, HM Lee, ... Investigative and Clinical Urology 61 (6), 588, 2020 | 4 | 2020 |
| Immune checkpoint inhibitors in patients with pretreated HodgkinEs lymphoma: A Korean single-center, retrospective study JY Hur, SE Yoon, SJ Kim, WS Kim Blood research 55 (2), 85, 2020 | 3 | 2020 |
| Atezolizumab in patients with pretreated urothelial cancer: a Korean single-center, retrospective study JY Hur, Y Kim, GY Kwon, M Kang, HH Sung, HG Jeon, BC Jeong, SI Seo, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2019 | 3 | 2019 |
| Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience JY Hur, JY Kim, JS Ahn, YH Im, J Lee, M Kwon, YH Park Cancers 12 (5), 1306, 2020 | 2 | 2020 |
| Hepatitis B virus reactivation in a chronic lymphocytic leukemia patient treated with ibrutinib JH Choi, JY Hur, YW Won Cancer research and treatment 55 (2), 704-705, 2023 | 1 | 2023 |
